Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 220.10K | 227.00K | 585.00K | 590.00K | -152.30K |
| Total Other Revenue | 258.00K | 266.00K | 345.00K | 347.90K | 285.80K |
| Total Revenue | 478.10K | 493.10K | 930.00K | 937.90K | 133.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 478.10K | 493.10K | 930.00K | 937.90K | 133.50K |
| SG&A Expenses | 1.72M | 1.77M | 1.53M | 1.54M | 2.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.96M | 5.12M | 4.91M | 4.96M | 6.92M |
| Operating Income | -4.48M | -4.62M | -3.98M | -4.02M | -6.78M |
| Income Before Tax | -4.34M | -4.47M | -3.14M | -3.17M | -7.68M |
| Income Tax Expenses | 8.50K | 8.80K | 2.70K | 2.70K | -1.10K |
| Earnings from Continuing Operations | -4.35M | -4.48M | -3.15M | -3.17M | -7.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.35M | -4.48M | -3.15M | -3.17M | -7.67M |
| EBIT | -4.48M | -4.62M | -3.98M | -4.02M | -6.78M |
| EBITDA | -4.43M | -4.57M | -3.95M | -3.99M | -5.96M |
| EPS Basic | -0.04 | -0.04 | -0.04 | -0.04 | -0.15 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.02 | -0.02 | -0.09 |
| EPS Diluted | -0.04 | -0.04 | -0.04 | -0.04 | -0.15 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.02 | -0.02 | -0.09 |
| Average Basic Shares Outstanding | 108.76M | 108.76M | 82.75M | 82.75M | 50.56M |
| Average Diluted Shares Outstanding | 108.76M | 108.76M | 82.75M | 82.75M | 50.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |